Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
8(80.0%)
Phase 2
1(10.0%)
Early Phase 1
1(10.0%)
10Total
Phase 1(8)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT06823167Phase 1Recruiting

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Role: lead

NCT07505771Early Phase 1Recruiting

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Role: lead

NCT07578571Phase 1Recruiting

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Role: lead

NCT07610005Phase 1Recruiting

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

Role: lead

NCT04871282Phase 2Active Not Recruiting

A Study of AL102 in Patients With Progressing Desmoid Tumors

Role: lead

NCT06841315Phase 1Completed

A Varegacestat Hepatic Impairment Study

Role: lead

NCT06845852Phase 1Completed

A Phase 1 Mass Balance Study of Varegacestat

Role: lead

NCT06855264Phase 1Completed

A Cardiac Liability Study of Varegacestat in Healthy Participants

Role: lead

NCT06677996Phase 1Completed

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

Role: lead

NCT05429021Phase 1Terminated

IMM-BCP-01 in Mild to Moderate COVID-19

Role: lead

All 10 trials loaded